Clinical Trials Browser

Phase 3 × Epstein-Barr Virus Infections × Lenalidomide × Clear all

NCT04084626 2022-01-05

PD1 Antibody and Lenalidomide as a Treatment for EBV-HLH or CAEBV

Phase 3 Unknown

Epstein-Barr Virus Infections